Trial Watch: Proteasomal inhibitors for anticancer therapy

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The ubiquitin-proteasome system (UPS) maintains protein homeostasis and regulates signaling pathways.
• UPS dysfunction is linked to aging and diseases, including cancer.
• Cancer cells rely on UPS integrity for survival and proliferation due to constant stress.

Purpose of the Study:

• To review the role of the UPS in oncogenesis and tumor progression.
• To summarize recent clinical studies on proteasome inhibitors in cancer therapy.
• To discuss challenges and future directions for UPS-targeted cancer treatments.

Main Methods:

• Review of preclinical and clinical investigations of UPS and proteasome inhibitors.
• Analysis of bortezomib and carfilzomib clinical trial data.
• Discussion of resistance mechanisms and biomarker development.

Main Results:

• Proteasome inhibitors like bortezomib and carfilzomib are approved for certain hematologic malignancies.
• Clinical activity is limited by off-target effects, resistance, and lack of predictive biomarkers.
• Efficacy against solid tumors remains poor.

Conclusions:

• The UPS is a critical target in oncology, with approved proteasome inhibitors showing efficacy in specific cancers.
• Overcoming resistance and improving efficacy, especially in solid tumors, requires further research.
• Development of novel UPS-targeting strategies and predictive biomarkers is essential for advancing cancer therapy.